Overcoming barriers to diabetes control in geriatrics

Hammouda, Emad I.

doi:10.1111/j.1742-1241.2010.02599.x

International Journal of Clinical Practice

2011

DOI: 10.1111/j.1742-1241.2010.02599.x

|View full text |Cite

Overcoming barriers to diabetes control in geriatrics

Emad I. Hammouda

Abstract: There is a need for extra care and overcoming barriers to diabetes control in old patients as a dynamic and a continuous task that needs coordination of healthcare systems and professionals at all levels of care.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2012

2018

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The residual risk is enhanced by inadequate remediation of multiple risk factors 20–22 and poor treatment adherence to multidrug regimens. 23,24 Improved use of evidence-based therapy in the United States have been accompanied by reductions in CVD events. 25 …”

mentioning

confidence: 99%

Modulating peroxisome proliferator–activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects

Rosenson

Wright

Farkouh

et al. 2012

American Heart Journal

View full text Add to dashboard Cite

Clinical trials of cardiovascular disease (CVD) prevention in patients with type 2 diabetes mellitus primarily have been directed at the modification of a single major risk factor; however, in trials that enroll patients with and without diabetes, the absolute risk in CVD events remains higher in patients with diabetes. Efforts to reduce the macrovascular and microvascular residual risk have been directed toward a multifactorial CVD risk-factor modification; nonetheless, long-term complications remain high. Dual-peroxisome proliferator–activated receptor (PPAR) α/γ agonists may offer opportunities to lower macrovascular and microvascular complications of type 2 diabetes mellitus beyond the reductions achieved with conventional risk-factor modification. The information presented elucidates the differentiation of compound-specific vs class-effect properties of PPARs as the basis for future development of a new candidate molecule. Prior experience with thiazolidinediones, an approved class of PPARγ agonists, and glitazars, investigational class of dual-PPARα/γ agonists, also provides important lessons about the risks and benefits of targeting a nuclear receptor while revealing some of the future challenges for regulatory approval.

show abstract

mentioning

confidence: 99%

Modulating peroxisome proliferator–activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects

Rosenson

Wright

Farkouh

et al. 2012

American Heart Journal

View full text Add to dashboard Cite

show abstract

Insulintherapie im Alter – eine qualitative Versorgungsstudie

Grundke

Klement

2018

GGP

View full text Add to dashboard Cite

Zusammenfassung Herausforderungen Eine effektive Verzahnung der Kooperation von Versorgungsebenen und Leistungserbringern hat zentrale Bedeutung für niedrige Hospitalisierungsraten sowie bedarfsgerechte medizinische und pflegerische Versorgung älterer insulinpflichtiger Typ-2-Diabetiker.1 Die zentralen Herausforderungen der berufsgruppenübergreifenden Zusammenarbeit bestehen darin, die Insulintherapie nicht nur an Stoffwechselzielen zu orientieren, sondern ebenso die Patientensicherheit, ökonomische Effizienz und individuelle Lebensqualitätsvorstellungen von Patienten und deren Angehörigen zu berücksichtigen. 1–3

show abstract

Insulintherapie im Alter

Grundke

Klement

2018

Diabetes aktuell

View full text Add to dashboard Cite

ZUSAMMENFASSUNGEine effektive Verzahnung der Kooperation von Versorgungsebenen und Leistungserbringern hat zentrale Bedeutung für niedrige Hospitalisierungsraten sowie bedarfsgerechte medizinische und pflegerische Versorgung älterer insulinpflichtiger Typ-2-Diabetiker 1. Die zentralen Herausforderungen der berufsgruppenübergreifenden Zusammenarbeit bestehen darin, die Insulintherapie nicht nur an Stoffwechselzielen zu orientieren, sondern ebenso die Patientensicherheit, ökonomische Effizienz und individuelle Lebensqualitätsvorstellungen von Patienten und deren Angehörigen zu berücksichtigen 1–3.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Overcoming barriers to diabetes control in geriatrics

Abstract: There is a need for extra care and overcoming barriers to diabetes control in old patients as a dynamic and a continuous task that needs coordination of healthcare systems and professionals at all levels of care.

Cited by 5 publications

References 18 publications

Modulating peroxisome proliferator–activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects

Modulating peroxisome proliferator–activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects

Insulintherapie im Alter – eine qualitative Versorgungsstudie

Insulintherapie im Alter

Contact Info

Product

Resources

About